Bliss GVS Pharma Q2 Results: Profit Dips, New Promoters Take Control

Revenue stood at Rs 243.98 crore, while Net Profit was reported at Rs 14.46 crore for the quarter ended September 30, 2026.

Reader Takeaway: New promoter takeover signals strategic change; declining quarterly earnings highlight immediate operational pressure for the new board.

What just happened

Bliss GVS Pharma has officially transitioned to new leadership. Anupam Rasayan India Ltd, working with Mates Visa Consultancy, completed the acquisition of a 50.07% stake as of September 28, 2026. This change in control has led to a full reconstitution of the company's Board of Directors.

Why this matters

The change in promoter marks a significant shift in corporate governance and ownership. While the company's financial results for the quarter were not impacted by this transition, shareholders are now waiting to see how the new management will steer the company’s business operations and product strategy moving forward.

Financial Performance

For the quarter ended September 30, 2026, revenue fell to Rs 243.98 crore compared to Rs 285.57 crore in the same period last year. Net profit also saw a decline, landing at Rs 14.46 crore against Rs 16.74 crore in Q2 FY2026. Notably, in its standalone results, the firm reversed an impairment provision of Rs 41.08 crore related to its Singapore subsidiary, Bliss GVS International Pte. Ltd., citing a recovery in the subsidiary's net worth.

Risks to watch

The primary risk remains the underlying decline in top-line growth. Investors should monitor whether the new management can stabilize revenue and improve operational efficiencies in the upcoming quarters.

What to track next

Watch for official investor communications regarding the new board's strategic priorities, potential shifts in business focus, and plans for the subsidiary operations under the new ownership structure.